Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
1.
Aging Clin Exp Res ; 33(2): 345-352, 2021 Feb.
Article de Anglais | MEDLINE | ID: mdl-32193850

RÉSUMÉ

AIMS: The objective of this study was to examine baseline frailty status (including cognitive deficits) and important clinical outcomes, to inform shared decision-making in older adults receiving transcatheter aortic valve implantation (TAVI). METHODS AND RESULTS: We conducted a prospective, observational study of 82 TAVI patients, recruited 2013 to 2015, with 2-year follow-up. Mean age was 83 years (standard deviation (SD) 4.7). Eighteen percent of the patients were frail, as assessed with an 8-item frailty scale. Fifteen patients (18%) had a Mini-Mental Status Examination (MMSE) score below 24 points at baseline, indicating cognitive impairment or dementia and five patients had an MMSE below 20 points. Mean New York Heart Association (NYHA) class at baseline and 6 months was 2.5 (SD 0.6) and 1.4 (SD 0.6), (p < 0.001). There was no change in mean Nottingham Extended Activities of Daily Living (NEADL) scale between baseline and 6 months, 54.2 (SD 11.5) and 54.5 (SD 10.3) points, respectively, mean difference 0.3 (p = 0.7). At 2 years, six patients (7%) had died, four (5%, n = 79) lived in a nursing home, four (5%) suffered from disabling stroke, and six (7%) contracted infective endocarditis. CONCLUSIONS: TAVI patients had improvement in symptoms and maintenance of activity of daily living at 6 months. They had low mortality and most patients lived in their own home 2 years after TAVI. Complications like death, stroke, and endocarditis occurred. Some patients had cognitive impairment before the procedure which might influence decision-making. Our findings may be used to develop pre-TAVI decision aids.


Sujet(s)
Sténose aortique , Fragilité , Remplacement valvulaire aortique par cathéter , Activités de la vie quotidienne , Sujet âgé , Sujet âgé de 80 ans ou plus , Valve aortique/chirurgie , Sténose aortique/chirurgie , Humains , Études prospectives , Facteurs de risque , Remplacement valvulaire aortique par cathéter/effets indésirables , Résultat thérapeutique
2.
Eur Heart J Qual Care Clin Outcomes ; 5(2): 153-160, 2019 04 01.
Article de Anglais | MEDLINE | ID: mdl-30256921

RÉSUMÉ

AIMS: Established surgical scores have limitations in delineating risk among candidates for transcatheter aortic valve implantation (TAVI). Assessment of frailty might help to estimate the mortality risk and identify patients likely to benefit from treatment. The aim of the study was to develop a frailty score to guide the decision for TAVI. METHODS AND RESULTS: We conducted a prospective observational study in patients ≥70 years referred for TAVI during 2011-15. A Heart Team had declined the patients for open heart surgery due to high risk but accepted them for TAVI. Prior to the procedure, a geriatric assessment (GA) was performed. Based on this, an 8-element frailty score with a 0-9 (least frail-most frail) scale was developed. A total of 142 patients, 54% women, mean age 83 (standard deviation 4) years, with severe and symptomatic aortic stenosis were assessed. All-cause 2 year mortality was 11%. The novel GA frailty score predicted 2-year mortality in Cox analyses, also when adjusted for age, gender, and logistic EuroSCORE [hazard ratio (HR) 1.75, 95% confidence interval (CI): 1.28-2.42, P < 0.001]. A receiver operating characteristic (ROC) curve analysis indicated that a GA frailty score cut-off at ≥4 predicted 2-year mortality with a specificity of 80% (95% CI: 73-86%) and a sensitivity of 60% (95% CI: 36-80%). The area under the curve was 0.81 (95% CI 0.71-0.90). CONCLUSION: A novel 8-element GA frailty score identified gradations in survival in patients declined for open heart surgery. Patients with higher GA frailty scores had significantly higher 2-year mortality after TAVI.


Sujet(s)
Sténose aortique/chirurgie , Personne âgée fragile/statistiques et données numériques , Fragilité/mortalité , Évaluation gériatrique/méthodes , Complications postopératoires , Appréciation des risques/méthodes , Remplacement valvulaire aortique par cathéter/effets indésirables , Sujet âgé , Sujet âgé de 80 ans ou plus , Valve aortique/chirurgie , Sténose aortique/mortalité , Femelle , Études de suivi , Humains , Mâle , Norvège/épidémiologie , Études prospectives , Facteurs de risque , Taux de survie/tendances , Facteurs temps
3.
Scand Cardiovasc J ; 44(5): 279-88, 2010 Oct.
Article de Anglais | MEDLINE | ID: mdl-20524905

RÉSUMÉ

OBJECTIVES: To evaluate the influence of competing risk (CR) non-cardiac death during long-term follow-up of revascularized patients on the interpretation of the cardiac outcomes. METHODS: Retrospectively, we compared outcomes estimated with the Kaplan-Meier and the cumulative incidence function (CIF) methods after a median 10.8 years follow-up in 1,234 consecutive patients (594 CABG, 640 PCI) undergoing first time non-emergent revascularization in a community cohort. RESULTS: Overall 301 (24.4%) patients died (27.3% in the CABG vs. 21.7% in the PCI group, p = 0.02). The causes of death were cardiac (10.3%) and non-cardiac (14.1%). CR analysis showed a similar probability of cardiac death (CIF 0.10 (95% CI 0.092, 0.18) vs. 0.093 (0.07, 0.12)) in the CABG and PCI treated patients, respectively. The probability for acute myocardial infarction (CIF 0.12 vs. 0.16 p < 0.001), congestive heart failure (CIF 0.15 vs. 0.09 p = 0.007) in the CABG and PCI group respectively, differed. The differences were also statistically significant after multivariate adjustment for the competing risks of death. For all outcomes the Kaplan-Meier method overestimated risk estimates. CONCLUSIONS: The competing risk adjusted probability for cardiac death, but not other cardiac endpoints are comparable in patients treated with either CABG or PCI after very long-term follow-up. The risk for all-cause death was mainly predicted by the occurrence of non-cardiac diseases.


Sujet(s)
Angioplastie coronaire par ballonnet/mortalité , Pontage aortocoronarien/mortalité , Maladie des artères coronaires/thérapie , Ajustement du risque , Sujet âgé , Angioplastie coronaire par ballonnet/effets indésirables , Cause de décès , Pontage aortocoronarien/effets indésirables , Maladie des artères coronaires/mortalité , Femelle , Études de suivi , Défaillance cardiaque/étiologie , Défaillance cardiaque/mortalité , Humains , Estimation de Kaplan-Meier , Mâle , Adulte d'âge moyen , Infarctus du myocarde/étiologie , Infarctus du myocarde/mortalité , Études rétrospectives , Résultat thérapeutique
4.
Tidsskr Nor Laegeforen ; 124(5): 644-7, 2004 Mar 04.
Article de Norvégien | MEDLINE | ID: mdl-15004610

RÉSUMÉ

The term unstable coronary syndromes represents a continuum of patients with unstable chest pain with or without small or large acute myocardial infarctions. There is a tendency towards an epidemiological shift to fewer large infarctions with ST elevation in the ECG (STEMI) to increased numbers of small infarctions without ST elevation (nSTEMI). Patients with unstable angina or nSTEMI should start antithrombotic medication with aspirin, heparin and clopidogrel upon arrival in hospital. Patients with medium or high risk of death or cardiac events will benefit from therapy with IIb/IIIa glycoprotein receptor inhibitors and should be referred for coronary angiography within 6-48 hours after arrival. Final therapy with percutaneous coronary intervention or coronary artery bypass surgery is indicated immediately after angiography or within a few days. Close follow-up with respect to epidemiological risk factors, diet, use of medication according to the results of large randomised studies will further reduce mortality and morbidity, in the short as well as the long term.


Sujet(s)
Infarctus du myocarde/traitement médicamenteux , Angine de poitrine/diagnostic , Angor instable/diagnostic , Coronarographie , Diagnostic différentiel , Électrocardiographie , Fibrinolytiques/administration et posologie , Études de suivi , Humains , Infarctus du myocarde/diagnostic , Infarctus du myocarde/physiopathologie , Antiagrégants plaquettaires/administration et posologie , Appréciation des risques
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...